Throughout your therapy, your provider will keep a close eye on your progress by tracking your mobility, pain levels, labs, and follow-up scans
GLP-1 agonists have been shown to reduce oxidative stress in diverse preclinical studies
BMI 27 with weight-related conditions, such as: Type 2 diabetes or prediabetes Hypertension High cholesterol Sleep apnea Fatty liver disease (NAFLD) PCOS Insulin resistance Patients in this range may be candidates because GLP-1 medications act on pathways related to blood sugar, appetite, and metabolic regulation
That makes five positive Phase 3 studies
The broader implication for market growth is a self-reinforcing ecosystem in which regulatory clarity, technology vendor concentration, and CRO operational scale collectively lower the cost and time to deploy DCT-enabled protocols for sponsors at every organizational scale